Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding

Overview

The study aims to describe the changes in Levothyroxine dosage requirements in patients with hypothyroidism started on enteral feeding, and assess whether giving levothyroxine on empty stomach affects the mean percentage increase expected in Levothyroxine dosage in these patients.

Full Title of Study: “The Effect of Holding Tube Feeding When Administering Levothyroxine on the Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2020

Detailed Description

The study will be a Randomized Controlled trial comparing the mean percentage of Levothyroxine dosage change in hypothyroid patients after the starting of enteral feeding in an inpatient setting in two different groups: a control group where Levothyroxine will be administered with continuous enteral nutrition, and an intervention group where enteral nutrition will be held for two hours before and two hours after the Levothyroxine administration.

The enrollment of eligible patients will be over two to three years and follow up will continue for the duration of the hospital stay or 12 weeks, which ever occurs earlier. Eligible patients will have thyroid function tests at enrollment (within three days of the starting of the tube feeding) and afterwards weekly. Levothyroxine dosage will be adjusted by the endocrinology research team according to the thyroid function results. Initial Levothyroxine dosage and subsequent dosages will be recorded and the mean percentage decrease or increase of Levothyroxine dosage required will be measured in each group. An eventual difference between the two groups mean percentage change will be tested for statistical significance.

Interventions

  • Drug: Levothyroxine
    • Administer Levothyroxine

Arms, Groups and Cohorts

  • Experimental: Levothyroxine on empty stomach
    • Levothyroxine will be given on empty stomach, by holding enteral feeding for 2 hours before and 2 hours after Levothyroxine administration
  • Active Comparator: Levothyroxine during feeding
    • Levothyroxine will be given while the enteral feeding is running

Clinical Trial Outcome Measures

Primary Measures

  • Mean percentage change of Levothyroxine dosage
    • Time Frame: 12 weeks
    • The Primary outcome will be the measurement of the mean percentage change of levothyroxine dosage ( end of the enrollment dose as compared to baseline dose) in each of the two comparative groups: The control group of patients receiving Levothyroxine during the tube feeding, and the intervention group of patients receiving Levothyroxine on empty stomach (two hours before and two hours after holding the feeding)

Participating in This Clinical Trial

Inclusion Criteria

  • Adults admitted to Maimonides Medical Center
  • Started on Enteral feeding within 3 days of enrollment: tube feeding, Percutaneous Endoscopic Gastrostomy or PEG tube feeding, or Jejunostomy tube feeding.
  • History of Hypothyroidism on a stable dose of Levothyroxine for at least four weeks prior to enteral feeding
  • TSH 0.2-10 mIU/ml at enrollment

Exclusion Criteria

  • Concomitant administration of medications that affect thyroid function test including Cholestyramine, Sucralfate, Amiodarone, Lithium, Dopamine, Dobutamine and Dilantin at enrollment.
  • Pregnancy
  • Known untreated disease or surgery of the small intestine specifically the Jejenum.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Jocelyne Karam
  • Collaborator
    • Maimonides Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Jocelyne Karam, Director, Division of Endocrinology – Maimonides Medical Center
  • Overall Official(s)
    • Jocelyne Karam, MD, Principal Investigator, Maimonides Medical Center
  • Overall Contact(s)
    • Jocelyne Karam, MD, 718-283-5906, jkaram@maimonidesmed.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.